Trial Profile
A Phase 1 Study of Nexvax2 Administered Subcutaneously After a Screening Gluten Food Challenge That Compares Relative Bioavailability With Intradermal Administration in Non-homozygous HLA-DQ2.5+ Adults With Celiac Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Aug 2020
Price :
$35
*
At a glance
- Drugs HLA DQ2 peptide vaccine (Primary) ; HLA DQ2 peptide vaccine (Primary)
- Indications Coeliac disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ImmusanT
- 13 Aug 2019 Results published in the Alimentary Pharmacology and Therapeutics
- 21 May 2019 According to a ImmusanT Media Release, data from this trial was presented as an oral presentation at the Digestive Disease Week Annual Conference 2019 in San Diego.
- 21 May 2019 Results published in the ImmusanT Media Release